<DOC>
	<DOCNO>NCT01284166</DOCNO>
	<brief_summary>This study investigate safety efficacy Triple Combination Therapy dorzolamide hydrochloride/brimonidine tartrate/timolol ophthalmic solution patient glaucoma ocular hypertension elevate IOP dorzolamide hydrochloride/timolol maleate combination therapy .</brief_summary>
	<brief_title>Safety Efficacy Triple Combination Therapy With Dorzolamide Hydrochloride / Brimonidine Tartrate / Timolol Ophthalmic Solution Patients With Glaucoma Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Dorzolamide</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Diagnosis ocular hypertension glaucoma eye Requires IOPlowering treatment eye Use dorzolamide carbonic anhydrase within 4 week Any active ocular disease ocular hypertension glaucoma ( eg , uveitis , ocular infection severe dry eye ) Required chronic use ocular medication study medication study ( intermittent use certain product eg , artificial tear permit ) Use oral , injectable topical ophthalmic steroid within 21 day Any eye laser surgery within 3 month Any intraocular surgery ( eg cataract surgery ) within 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>